These results suggest that Ubenimex inhibits the expression of MDR associated proteins, including P-gp, MRP3 and/or MRP2, to promote drug accumulation in MDR HCC cells, and that these effects correlate with the down-regulation of Pim-3. Here, PIM3 is linked to hepatocellular carcinoma.